化疗相关性恶心呕吐的回顾性研究

Adherence to NCCN antiemesis guideline for chemotherapy induced nausea and vomiting: A retrospective study in changhai hospital

目的调查肿瘤患者在化疗期间止吐药物的应用情况,为合理用药提供参考。方法回顾性分析长海医院肿瘤科2016年6月至2017年5月期间收治533例肿瘤患者的病历资料,收集患者年龄、原发肿瘤诊断、化疗方案及其致吐性、指南依从性等。参考NCCN指南分别对接受单日化疗方案和多日化疗方案的患者资料进行描述性统计分析。结果 533例接受化疗的患者中5-HT_3受体拮抗剂预防性止吐治疗比例达100%。其中多日化疗的高度致吐风险方案的指南符合率高于单日化疗(22.29%vs.15.79%)。结论肿瘤患者预防性应用止吐药物以5-HT_3受体拮抗剂联合激素为主,止吐药物使用的指南符合率低与阿瑞匹坦的可及性有关。

Objective To investigate the application of antiemetic drugs in cancer patients during chemotherapy,so as to provide reference for rational drug use. Methods Clinical data of 533 tumor patients receiving chemotherapy in changhai hospital from June 2016 to May 2017 were retrospectively analyzed,and variables including age,primary tumor diagnosis,chemotherapy regimen and its emetogenic risk,adherence to guidline were collected. In this study,a descriptive statistical analysis was applied on the data of patients receiving single day or multiday chemotherapy regimen,according to NCCN antiemesis guideline. Results In 533 patients receiving chemotherapy,the proportion of 5-HT3 antagonist preventive antiemetic therapy was 100%. Among them,the guidelines for high risk of vomiting were in accordance with the rate of chemotherapy. The daily chemotherapy was higher than that of the single day chemotherapy,which was 22. 29% and 15. 79% respectively. Conclusion The prophylactic use of antiemetic drugs in cancer patients is based on 5-HT3 receptor antagonist combined with hormone,and the low compliance rate of antiemetic drug use is associated with the accessibility of aprepitant.